In September, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna’s COVID-19 mRNA vaccine Spikevax ... Faced with commercial challenges, Moderna ...

Branded as Spikevax, Moderna's (NASDAQ:MRNA) COVID-19 shot is indicated in the EU for active immunization of people aged six months and older. "Diversity of supply and availability of vaccine ...

The 15-year-old star of a film about a schoolgirl forced to marry an older man is evangelical about her role - despite the fact that her community in north-western Kenya might see it as a betrayal ...

Moderna on Friday said it received approval for supplying its Spikevax Covid-19 vaccine to the European Union, Norway and North Macedonia following a tender process. Under the agreement ...

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's Covid-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for ...

AI-Fueled Hope is Insufficient to Heal MRNA I’m bearish on Moderna due to its prolonged path to profitability, lack of immediate catalysts, and reliance on a single commercial product, Spikevax.

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.

Moderna's trailing-12-month revenue is just over $5 billion, down by 77% from three years ago. Even with ongoing updates to its Spikevax jab for coronavirus, there simply isn't as much demand for ...